Lymphomas & Lymphoid Neoplasia

Lymphomas & Lymphoid Neoplasia

A collection of features and news articles published in ASH Clinical News related to lymphomas and lymphoid neoplasia.

Certain Non-Hodgkin Lymphoma Subtypes Carry Higher Risk of Infection-Related Solid Tumor Cancers

Various subtypes of non-Hodgkin lymphoma (NHL), including diffuse large B-cell lymphoma (DLBCL) and marginal zone lymphoma (MZL), carry a risk for second infection-related solid...
On location

Allogeneic or Autologous Transplant for Peripheral T Cell Lymphoma?

In a final analysis from the Autologous or Allogeneic Transplantation in T-Cell Lymphoma (AATT) trial, researchers found no differences in survival outcomes between consolidation...

FDA Orders Allergan to Recall Textured Breast Implants Over Cancer Risk

The U.S. Food and Drug Administration (FDA) has requested that Allergan recall its BIOCELL textured breast implants due to a risk of breast implant-associated...
WIB_icon

Short, Aggressive Antibiotic Therapy Inhibits Lymphocyte Proliferation in CTCL

According to a study published in Blood, patients with advanced-stage cutaneous T cell lymphoma (CTCL) a short, yet aggressive, antibiotic regimen inhibited disease activity...

Polatuzumab Vedotin-piiq Receives FDA Approval for DLBCL

The FDA has approved the CD79b-directed antibody drug conjugate polatuzumab vedotin-piiq, in combination with bendamustine and rituximab (BR), to treat adults with relapsed or...
On location

Bispecific Antibody REGN1979 Shows Promising Efficacy in Relapsed/Refractory Non-Hodgkin Lymphomas

In a small phase I study of patients with relapsed/refractory non-Hodgkin lymphoma (NHL), approximately half of patients responded to treatment with REGN1979, an anti-CD20...
WIB_icon

Evaluating Safety and Efficacy of Venetoclax Plus R-CHOP in Non-Hodgkin Lymphoma

According to results from the phase Ib CAVALLI study, treatment with the oral BCL2 inhibitor venetoclax, combined with standard immunochemotherapy, induced high response rates...

Study Finds Standard R-CHOP Bests Dose-Adjusted EPOCH-R in DLBCL

In an update from the phase III intergroup Alliance/CALGB 50303 trial, treatment with frontline dose-adjusted (DA) EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, rituximab) failed...

FDA to Close Its Controversial Medical Device Reporting Program

In what is being called a victory for patients and consumers, the U.S. Food and Drug Administration (FDA) said that it is ending its...
WIB_icon

Post-Transplant Pembrolizumab Consolidation Improves PFS in Relapsed/Refractory Hodgkin Lymphoma

In patients with high-risk, relapsed/refractory classical Hodgkin lymphoma (cHL) who have undergone autologous hematopoietic cell transplantation (AHCT), consolidation therapy with the PD-1 inhibitor pembrolizumab...
Advertisement

Current Issue

September 2019 Volume 5 Issue 11

September 2019, Volume 5, Issue 11

This issue explores politics in the exam room, demystifies proteomic analysis in hematology, and more.